Insights into the Phase III CERVINO trial: ABBV-383 for R/R myeloma

ABBV-383 - Upcoming Myeloma TreatmentПодробнее

Phase I study of ABBV383, a novel BCMAxCD3 bispecific antibody, in R/R multiple myelomaПодробнее

Updated safety and efficacy results of Abbv-383, a novel BsAb, in patients with R/R multiple myelomaПодробнее

Phase I study of ABBV-383, a BCMA×CD3 bispecific antibody, in R/R myelomaПодробнее

Updated Safety and Efficacy Results of Abbv-383 | Ravi Vij, MD, MBA | ASH 2023Подробнее

KarMMa-3: Phase III trial of idecabtagene vicleucel in R/R myelomaПодробнее

ASH23: Abbv-383 BCMA x CD3 Bispecific Antibody for Relapsed/Refractory Myeloma | Ravi Vij, MD, MBAПодробнее

AbbVie 383 - Guest LectureПодробнее

Efficacy, Safety, and Determination of ABBV-383, a BCMA Bispecific Antibody, in Patients with RRMMПодробнее

Phase I trial evaluating a gamma secretase inhibitor in combination with CAR-T cells in R/R myelomaПодробнее

Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMMПодробнее

Phase III trial of RVd induction with or without isatuximab in newly diagnosed myelomaПодробнее

Comment: MONARCH 3 trial: Abemaciclib for advanced breast cancerПодробнее

Phase I trial of a BCMA-CD3 bispecific antibody in R/R myelomaПодробнее

Benefit and risk analysis from the phase III OPTiM trialПодробнее

Understanding Clinical TrialsПодробнее

B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager CC-93269 in Patients with RR Multiple MyelomaПодробнее

Phase III trial of intensification and consolidation therapy in newly diagnosed myelomaПодробнее

Overview of the Phase III ENHANCE trial schemaПодробнее